Vera Therapeutics VERA Stock
Vera Therapeutics Price Chart
Vera Therapeutics VERA Financial and Trading Overview
| Vera Therapeutics stock price | 34.6 USD |
| Previous Close | 32.28 USD |
| Open | 32.25 USD |
| Bid | 22.14 USD x 100 |
| Ask | 38.91 USD x 200 |
| Day's Range | 32.02 - 35.09 USD |
| 52 Week Range | 21.15 - 56.05 USD |
| Volume | 2.41M USD |
| Avg. Volume | 2M USD |
| Market Cap | 2.43B USD |
| Beta (5Y Monthly) | 0.954 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.51 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 77.14 USD |
VERA Valuation Measures
| Enterprise Value | 2.01B USD |
| Trailing P/E | N/A |
| Forward P/E | -7.639503 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.9502387 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.835 |
Trading Information
Vera Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.954 |
| 52-Week Change | 49.60% |
| S&P500 52-Week Change | 18.35% |
| 52 Week High | 56.05 USD |
| 52 Week Low | 21.15 USD |
| 50-Day Moving Average | 36.15 USD |
| 200-Day Moving Average | 39.1 USD |
VERA Share Statistics
| Avg. Volume (3 month) | 2M USD |
| Avg. Daily Volume (10-Days) | 2.09M USD |
| Shares Outstanding | 72.06M |
| Float | 52.39M |
| Short Ratio | 6.6 |
| % Held by Insiders | 0.95% |
| % Held by Institutions | 117.96% |
| Shares Short | 15.28M |
| Short % of Float | 24.13% |
| Short % of Shares Outstanding | 21.20% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -46.75% |
| Return on Equity (ttm) | -91.75% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -415224000 USD |
| Net Income Avi to Common (ttm) | -401895008 USD |
| Diluted EPS (ttm) | -6.13 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 499.16M USD |
| Total Cash Per Share (mrq) | 6.93 USD |
| Total Debt (mrq) | 76.91M USD |
| Total Debt/Equity (mrq) | 18.86 USD |
| Current Ratio (mrq) | 10.916 |
| Book Value Per Share (mrq) | 5.667 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -338652992 USD |
| Levered Free Cash Flow (ttm) | -212947376 USD |
Profile of Vera Therapeutics
| Country | United States |
| State | CA |
| City | Brisbane |
| Address | 2000 Sierra Point Parkway |
| ZIP | 94005 |
| Phone | 650 770 0077 |
| Website | https://veratx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 361 |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Q&A For Vera Therapeutics Stock
What is a current VERA stock price?
Vera Therapeutics VERA stock price today per share is 34.6 USD.
How to purchase Vera Therapeutics stock?
You can buy VERA shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vera Therapeutics?
The stock symbol or ticker of Vera Therapeutics is VERA.
Which industry does the Vera Therapeutics company belong to?
The Vera Therapeutics industry is Biotechnology.
How many shares does Vera Therapeutics have in circulation?
The max supply of Vera Therapeutics shares is 72.06M.
What is Vera Therapeutics Price to Earnings Ratio (PE Ratio)?
Vera Therapeutics PE Ratio is now.
What was Vera Therapeutics earnings per share over the trailing 12 months (TTM)?
Vera Therapeutics EPS is -5.51 USD over the trailing 12 months.
Which sector does the Vera Therapeutics company belong to?
The Vera Therapeutics sector is Healthcare.
Vera Therapeutics VERA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26541.35 USD — |
+1.57
|
6.38B USD — | 26273.87 USD — | 26553.9 USD — | — - | 6.38B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2335.56 USD — |
+0.55
|
— — | 2329.25 USD — | 2344.13 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1367.92 USD — |
-0.35
|
— — | 1362.44 USD — | 1374.14 USD — | — - | — — |
- {{ link.label }} {{link}}
